logo
Plus   Neg
Share
Email

MorphoSys, Incyte Agree To Co-commercialize Tafasitamab In The U.S.

MorphoSys AG (MOR,MPSYY.PK) and Incyte Corp. (INCY) have agreed on a collaboration and license agreement to further develop and commercialize MorphoSys' anti-CD19 antibody tafasitamab (MOR208) globally. MorphoSys and Incyte will co-commercialize tafasitamab in the U.S. Incyte has exclusive commercialization rights outside of the U.S.

Tafasitamab is an Fc-engineered antibody currently in clinical development for the treatment of B cell malignancies. MorphoSys recently submitted a Biologics License Application for tafasitamab, in combination with lenalidomide, to the FDA for the treatment of relapsed/refractory diffuse large B cell lymphoma.

MorphoSys will receive an upfront payment of $750 million. Incyte will make an equity investment into MorphoSys of $150 million in new American Depositary Shares (ADS) of MorphoSys. Under the terms of the agreement, MorphoSys will be also eligible to receive milestone payments amounting to up to $1.1 billion.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Apple is tracking iPhones that were stolen from its retail stores in recent days during the civil unrest, according to reports citing a warning message popping up on the stolen iPhones. Four current and former senior executives from two major broiler chicken producers, including Pilgrim's Pride CEO Jayson Penn, have been indicted for price fixing. Kezar Life Sciences, Inc. (KZR) - Shares of the clinical-stage biotechnology company soared nearly 80% after closing bell. The company's lead drug candidate is KZR-616, a selective inhibitor of immunoproteasome that plays a crucial role in the immune system. KZR-616 is under a phase Ib/II study in...
Follow RTT